What Wörwag Pharma does

Wörwag Pharma is a family-owned German pharmaceutical company founded in 1971 in Stuttgart, headquartered in Böblingen, and operating as a GmbH & Co. KG. It specializes in biofactor products — vitamins, minerals, trace elements, and selected herbal actives — for the prevention and treatment of lifestyle-related and metabolic diseases, organized around four therapeutic areas: diabetic comorbidities (notably diabetic polyneuropathy and fatty liver), nervous system health, immune support, and musculoskeletal health. The portfolio spans prescription medicines (e.g., Thiogamma 600 oral, benfotiamine formulations), OTC products (B12 Ankermann, Milgamma, Zinkorot 25, magnerot, Vitagamma), and dietary supplements (ReDia, Lagosa Triplex), with proprietary high-bioavailability formulations such as benfotiamine developed by the founder and the patented ReDia HPMC fiber product. Products are sold in 35+ countries, frequently as category leaders, with deepest historic roots in Central and Eastern Europe and accelerating growth in Asia (Vietnam, Thailand, Philippines, Kazakhstan) and South America (Peru).

The company generates revenue through pharmaceutical product sales distributed via retail pharmacies, pharmacy chains, and pharmaceutical wholesalers, supported by a field sales force that engages doctors and pharmacists, an HCP portal (Fachkreise) with CME-certified content, and a global Health Academy webinar series launched in 2026. Direct pharmacy ordering is enabled through the PharmaMall e-commerce storefront and the MSV3 electronic data interchange, alongside traditional phone/email channels. Wörwag has built vertically integrated manufacturing through the 2021 acquisition of Sensilab (now Wörwag Pharma Operations in Łódź, Poland) and the 2023 acquisition of Mauermann Arzneimittel (now Wörwag Pharma Production in Pöcking, Germany), which together accounted for 42% of packages sold and 33% of the product portfolio from own production in 2025. Family ownership (Wörwag family), a managing-director governance model with Jochen Schlindwein as CEO and Gerhard Mayer as CFO, and a ~1,500-employee workforce across 25+ nationalities support a private, founder-anchored operating model.

Name

Wörwag Pharma

Legal name

Wörwag Pharma GmbH & Co. KG

Website

https://woerwagpharma.de

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Wörwag Pharma is a family-owned German pharmaceutical company that develops and sells biofactor products (vitamins, minerals, trace elements) for prevention and treatment of lifestyle diseases, with a focus on diabetic comorbidities, nervous system, immune, and musculoskeletal health across 35+ markets.

Ownership category

akta.pro rank

Product category

Pharmaceuticals (Biofactor Medicines and Supplements)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium) (AFAKAJAD), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical products
• Biofactor supplements
• OTC medicines
• Prescription medications
• Dietary supplements

Headquarters

HQ city

Böblingen

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products: Wörwag Pharma generates revenue through prescription medications (verschreibungspflichtige Präparate), OTC medicines, and dietary supplements. Products are sold across 35+ markets, often as market leaders in their categories
2. Pharmacy and wholesale distribution: Products distributed through pharmacies and wholesale channels. Ordering available via PharmaMall online shop, MSV3 electronic interface, telephone, and email

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

Core offering

Wörwag Pharma develops, manufactures, and sells pharmaceutical products based on biofactors—vitamins, minerals, and trace elements—for the prevention and treatment of lifestyle diseases. The portfolio includes prescription medications, OTC medicines, and dietary supplements focused on diabetic comorbidities, neurological conditions, immune support, and musculoskeletal health, sold across more than 35 markets. Manufacturing is carried out at the company's own production sites in Pöcking, Bavaria and Łódża, Poland.

Product overview

Wörwag Pharma is a pharmaceutical company specializing in biofactor products (vitamins, minerals, trace elements) and herbal ingredients for over 50 years. The company offers prescription preparations, OTC medicines, and dietary supplements focused on four therapeutic areas: diabetic comorbidities (including diabetic polyneuropathy), nervous system disorders, immune system support, and musculoskeletal health. Core products include B12 Ankermann (vitamin B12), benfotiamine (B1 derivative for diabetic complications), Lagosa Triplex® (new heart-liver-metabolism support), ReDia® (blood sugar management fiber supplement), Zinkorot® 25 (zinc), magnerot® (magnesium), milgamma® protekt (B vitamins for nervous system), Vitagamma®, and Thiogamma® 600 oral. The portfolio spans prescription pharmaceuticals, OTC medications, and dietary supplements available in 35+ markets worldwide, often as market leaders.

Differentiator

Problem solved

Functional benefit

Brands

• Wörwag Pharma Operations: Manufacturing operations site in Łódź, Poland
• Wörwag Pharma Production
• Health Academy

Products and services

• B12 Ankermann Vitamin B12 supplement product addressing vitamin B1 deficiency with high bioavailability. Achieved above-average strong growth in Germany in 2025, expanding its presence in pharmacy and patient markets.
• Lagosa Triplex® Scientifically formulated nutrient combination supporting the natural function of heart, liver, and lipid metabolism, based on current scientific findings with high bioavailability.
• ReDia® Innovative dietary fiber supplement with patented formula containing hydroxypropyl methylcellulose (HPMC). Reduces post-meal blood sugar spikes by forming a gel-like consistency in the stomach. Vegan, gluten-free, sugar-free, and lactose-free.
• Benfotiamine Vitamin B1 derivative developed by company founder Dr. Fritz Wörwag into a milestone therapy for diabetic comorbidities, featuring high bioavailability for protecting against vitamin B1 deficiency.
• Zinkorot® 25 Zinc supplement containing 25mg zinc in organic compound with orotic acid. Highest-dose zinc supplement available OTC in German pharmacies. Used for treating zinc deficiency states and supporting immune function.
• milgamma® protekt Vitamin B product line supporting nervous system health and neurological function.
• Thiogamma® 600 oral Prescription alpha-lipoic acid product for diabetic polyneuropathy treatment.
• magnerot® CLASSIC N Magnesium supplement product for supporting musculoskeletal health and normal bodily functions.

Quantifiable outcome

• 8.3% organic revenue growth in 2025, reaching €358.8 million
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Mauermann Arzneimittel KG (acquired)coreStrategic or Co-development Partner · 1 September 2023Acquired contract manufacturer Mauermann Arzneimittel KG in September 2023, renamed to Wörwag Pharma Production GmbH & Co. KG (WPP). Located in Pöcking, Bavaria with approximately 60 employees. Site produces solid oral dosage forms including granulation, drying, coating, and packaging. 45+ years of existing relationship prior to acquisition.
• Sensilab (acquired)coreStrategic or Co-development Partner · 1 May 2021Acquired Sensilab contract manufacturer in Poland, forming Wörwag Pharma Operations (WPO) in Łódź. Core component of international supply capabilities alongside WPP Pöcking site.
• DocCheck Medical Services GmbHcoreTechnology or IntegrationHealthcare professional authentication service enabling secure access to Fachkreise portal with prescription product information. Uses OAuth2 authentication. Compliance with German Heilmittelwerbegesetz (HWG) requirements for medical professional access.
• TWT Group GmbHminorImplementation/ SI/ Consulting PartnerDigital agency responsible for website conception, web design, software development, hosting and ongoing support for www.woerwagpharma.de.
• Herrnhuter Missionshilfe e.V.minorOthers25+ year CSR partnership supporting education and poverty relief in Tanzania. Projects include vocational schools in Songea, Namtumbo, Zanzibar, and Ndola Zambia. Wörwag family and company support through donations matched euro-for-euro.

Scale indicators16 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• STADA Arzneimittel AG: STADA is a major European specialty pharma company (now PE-owned) with broad generics and OTC portfolios including vitamins and biofactor products. Comparable in German heritage and OTC/supplement positioning but operates at substantially larger scale and broader therapeutic scope.
• Dermapharm Holding SE: Dermapharm is a larger German specialty pharmaceutical company with a broad portfolio including branded generics, OTC, and dietary supplements across multiple therapeutic categories. Comparable in its vertically integrated German manufacturing model and portfolio breadth, but operates at a larger scale.
• Steigerwald (Bayer Consumer Health): Steigerwald is a German manufacturer of herbal medicines (notably Iberogast) now part of Bayer Consumer Health. Comparable in its German specialty pharma heritage with scientifically formulated natural/botanical products, though now operates as part of a much larger global consumer health conglomerate.

Direct peers

• Bionorica SE: Bionorica is a German family-owned pharmaceutical company specializing in phytopharmaceutical (herbal) medicines for respiratory, urinary, and metabolic conditions. Comparable as a German family-owned specialty pharma with scientifically substantiated natural-ingredient products and strong international presence.
• Hermes Arzneimittel GmbH: Hermes is a German manufacturer of OTC medicines, dietary supplements, and natural health products including vitamin and mineral formulations. Comparable in size and product category focus with similar OTC/supplement distribution model and German pharma heritage.
• Pharma Stulln GmbH: Pharma Stulln is a German specialty pharmaceutical manufacturer of sterile ophthalmic preparations and selected supplements. Comparable as a German mid-market specialty pharma with focus on specific therapeutic niches and pharmacy distribution.
• Hevert Arzneimittel: Hevert is a German family-owned pharmaceutical company specializing in natural medicine, vitamins, minerals, and homeopathic preparations. Directly comparable to Wörwag in its family-owned structure, German heritage, and focus on micronutrient and natural remedy portfolios across similar therapeutic areas.
• Cesra Arzneimittel GmbH: Cesra is a German pharmaceutical company producing homeopathic and natural medicines including herbal and biofactor preparations. Comparable as a smaller German specialty pharma with natural-ingredient focus and pharmacy-channel distribution model.
• Biologische Heilmittel Heel: Heel is a German pharmaceutical company developing biological medicines from natural ingredients for self-medication and complementary therapy. Comparable in its German heritage, scientific substantiation of natural/biofactor products, and focus on lifestyle-related conditions with global distribution.
• Mibe GmbH Arzneimittel: Mibe is a German specialty pharmaceutical manufacturer offering branded generics and OTC products including vitamin and mineral supplements. Comparable to Wörwag in mid-market German pharma positioning with vertically integrated production and a mixed Rx/OTC/dietary supplement portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/100065250440435
• LinkedInlinkedin.com/company/woerwag-pharma
• Xx.com/woerwagpharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wörwag Pharma